Investigation of organic solvent-mediated carcinogenic mechanisms of bile duct cancer
Project/Area Number |
26670073
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Medical pharmacy
|
Research Institution | The University of Tokyo |
Principal Investigator |
TAKADA Tappei 東京大学, 医学部附属病院, 講師 (90376468)
|
Co-Investigator(Kenkyū-buntansha) |
TOYODA Yu 東京大学, 医学部附属病院, 特任助教 (80650340)
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 胆汁排泄 / トランスポーター / 胆管側膜輸送体 |
Outline of Final Research Achievements |
Some young employees who had a long history of exposure to halogenated hydrocarbon solvents, composed mostly of 1,2-dichloropropane, developed occupational cholangiocarcinoma. Although this dihaloalkane has been used in various industrial fields, there has been no biological evidence explaining the cholangiocarcinoma latency, as well as little understanding of general cholangiocarcinoma risk. In the present study, we explored the biliary excretion of 1,2-DCP metabolites by an untargeted metabolomics approach and the related molecular mechanisms with in vitro and in vivo experiments. We found that 1,2-DCP was conjugated with glutathione in the liver, and that the glutathione-conjugated forms of 1,2-DCP, including a potential carcinogen that contains a chloride atom, were excreted into bile by the bile canalicular membrane transporter, ABCC2. Our findings would contribute to uncover the latent mechanism by which the chronic exposure to 1,2-DCP increases cholangiocarcinoma risk.
|
Report
(3 results)
Research Products
(12 results)